ReWalk Robotics Ltd. (LFWD)
NASDAQ: LFWD · IEX Real-Time Price · USD
4.780
+0.030 (0.63%)
May 1, 2024, 3:25 PM EDT - Market open
ReWalk Robotics Revenue
In the year 2023, ReWalk Robotics had annual revenue of $13.85M with 151.39% growth. Revenue in the quarter ending December 31, 2023 was $6.88M with 215.92% year-over-year growth.
Revenue (ttm)
$13.85M
Revenue Growth
+151.39%
P/S Ratio
2.88
Revenue / Employee
$128,278
Employees
108
Market Cap
40.62M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | 4.87M | -1.67M | -25.55% |
| Dec 31, 2018 | 6.55M | -1.21M | -15.58% |
| Dec 31, 2017 | 7.75M | 1.88M | 32.10% |
| Dec 31, 2016 | 5.87M | 2.12M | 56.67% |
| Dec 31, 2015 | 3.75M | -205.00K | -5.19% |
| Dec 31, 2014 | 3.95M | 2.36M | 148.80% |
| Dec 31, 2013 | 1.59M | 616.00K | 63.37% |
| Dec 31, 2012 | 972.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rapid Micro Biosystems | 22.52M |
| Cara Therapeutics | 20.97M |
| Ocuphire Pharma | 19.05M |
| ImmuCell | 17.47M |
| iCAD, Inc. | 17.32M |
| Aspira Women's Health | 9.15M |
| Dyadic International | 2.90M |
LFWD News
- 12 days ago - Lifeward Announces the Appointment of Mike Swinford to its Board of Directors - GlobeNewsWire
- 19 days ago - Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton - GlobeNewsWire
- 4 weeks ago - Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate - GlobeNewsWire
- 5 weeks ago - VA STAND Act introduced in the United States Senate - GlobeNewsWire
- 7 weeks ago - Lifeward Announces Reverse Share Split - GlobeNewsWire
- 7 weeks ago - ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy - GlobeNewsWire
- 2 months ago - Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be c - GlobeNewsWire
- 2 months ago - Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire